Kazia Therapeutics Ltd's (ASX:KZA) (NASDAQ:KZIA) James Garner discusses with Proactive's Andrew Scott the news it's signed a deal with Simcere to commercialise paxalisib in China. It's the second out-licensing transaction that Kazia has done in a month, following the sale of Cantrixil to Oasmia in early March. Paxalisib is a brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is disordered in the vast majority of patients with glioblastoma, the most common and most aggressive form of primary brain cancer.
Kazia Therapeutics secures deal to commercialise paxalisib in China
